Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can magnetic brain stimulation keep depression at bay longer than a drug?

NCT ID NCT07760168

Disease control Sponsor: All India Institute of Medical Sciences, Bhubaneswar Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial tests whether maintenance rTMS—a non-invasive brain stimulation technique—can prevent depression from returning better than the medication quetiapine in people with treatment-resistant depression. After an initial course of rTMS, participants are randomly assigned to receive either monthly maintenance rTMS sessions or daily quetiapine for three months. Researchers track depression symptoms, overall improvement, side effects, and a blood marker called BDNF to see which approach offers longer-lasting relief.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Repetitive transcranial magnetic stimulation (rTMS) and quetiapine
What this could lead to
If maintenance rTMS works better than quetiapine, it could offer a drug-free way to keep depression from returning in people who haven't responded to standard treatments.
What could go wrong
This is a relatively small trial, and results may not apply to everyone. rTMS can cause side effects like headache or scalp discomfort, and quetiapine has its own risks, including drowsiness and weight gain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 68 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients of both genders, between the ages 18- 60 years 2. Clinically diagnosed as depression according to ICD-11. 3. Diagnosis of treatment resistance depression according to US-FDA. 4. On stable dosing of antidepressant venlafaxine 150 mg per day. 5. Right-handed. Exclusion Criteria: 1. Pregnant or lactating women. 2. Any kind of psychiatric emergency (E.g., Suicide risk, Catatonia, aggression or excitement) 3. Any co-morbid neurological disease 1. History of seizure/ epilepsy. 2. History of migraine. 3. History of head trauma/ organic brain condition. 4. Any contraindications to rTMS procedure: 1. Metallic or electronic implants in the brain or heart, or any cochlear implants 2. Injury or local lesion in the scalp/head.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Treatment resistant depression (TRD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Depressive Disorder, Treatment-Resistant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Treatment resistant depression (TRD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.